AVGR Avinger Inc

AVINGER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Avinger, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Avinger, Inc. (“Avinger” or the “Company”) (NASDAQ:AVGR) of the filing of a securities lawsuit against the Company.

If you invested in Avinger stock or options pursuant to the Company’s IPO and would like to discuss your legal rights, click here: www.faruqilaw.com/AVGR. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].

The lawsuit has been filed in the California Superior Court in San Mateo County on behalf of all those who purchased Avinger common stock traceable to the Company’s January 30, 2015 initial public stock offering (the “IPO”). The case, Lindsay Grotewiel vs. Avinger, Inc., et al, No. 17CIV02240 was filed on May 22, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Avinger did not have adequate sales and marketing personnel to increase sales of its lumivascular platform products and to commercialize Pantheris; (2) Avinger had already experienced problems with the robustness of its lumivascular platform devices, including Pantheris; (3) physicians and hospitals were requiring more extensive and comprehensive training and education on the benefits of Avinger’s products to convince them to adopt and implement Avinger’s lumivascular platform products compared to competing products and procedures available in the market; (4) in turn, Avinger would not be able to achieve a rapid ramp rate for increased sales of its lumivascular platform; and (5) as a result, Avinger was experiencing lower sales and revenues.

The lawsuit claims that as a result of the aforementioned, when the true details entered the market, investors suffered damages.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Avinger’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

EN
13/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avinger Inc

 PRESS RELEASE

Avinger Reports Third Quarter 2019 Financial Results

Avinger Reports Third Quarter 2019 Financial Results Increased Utilization Drives 33% Growth in Catheter Sales and Gross Margin ExpansionTotal Pantheris Revenue Increases 81% Year-over-Year REDWOOD CITY, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended September 30, 2019. Third Quarter Highlights Increased revenue 19% year-...

 PRESS RELEASE

Avinger Closes $4.5 Million Equity Offering

Avinger Closes $4.5 Million Equity Offering REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to ...

 PRESS RELEASE

Avinger Prices $4.5 Million Underwritten Public Offering of Common Sto...

Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 3,813,559 shares of the Company’s common stock at a price of $1.18 per share. The Comp...

 PRESS RELEASE

Avinger Announces Proposed Underwritten Public Offering of Common Stoc...

Avinger Announces Proposed Underwritten Public Offering of Common Stock REDWOOD CITY, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the Company expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover over-allotments, if any. The Company intends to ...

 PRESS RELEASE

Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019

Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019 Revenue Growth Fuels Strong Operating MetricsPantheris SV Limited Launch at Key U.S. Sites in July REDWOOD CITY, Calif., July 31, 2019 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the quarter ended June 30, 2019. Second Quarter and Recent Highlights Increased revenue 26% from the first quart...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch